Sign in to continue:

Sunday, March 8th, 2026

Hurco Companies, Inc. Q1 2026 Quarterly Report: Financial Statements, Analysis, and SEC Filings





Hurco Companies, Inc. Q1 2026 Earnings Report: Key Takeaways for Investors

Hurco Companies, Inc. Q1 2026 Earnings Report: Key Takeaways for Investors

Overview

Hurco Companies, Inc. (NASDAQ: HURC) has released its quarterly report for the fiscal quarter ended January 31, 2026. The company, which is a manufacturer and seller of computerized machine tools, reported its financial results and provided comprehensive information on its performance, financial position, and risks for the first quarter of fiscal 2026.

Key Financial Highlights

  • Revenue: The company generated \$46.4 million in revenue for the three months ended January 31, 2026, compared to \$54.5 million in the same period last year. This represents a notable year-over-year decline, signaling a contraction in sales.
  • Net Income (Loss): Hurco reported a net loss of \$3.8 million for the quarter, a significant reversal from net income of \$4.3 million in the prior year’s quarter. This is a potentially price-sensitive development and may raise concerns among shareholders about the company’s current trajectory.
  • Operating Income: The company experienced an operating loss, further reflecting the challenging market environment and/or internal company issues.
  • Earnings Per Share (EPS): Basic and diluted loss per share were both \$0.54 for Q1 2026, compared to earnings per share of \$0.67 in the same period last year.
  • Gross Margin and Expenses: Details on selling, general, and administrative expenses, as well as other income and investment income, are included, with the trend pointing toward increased costs relative to shrinking revenues.

Balance Sheet Position

  • Total Assets: \$261.5 million as of January 31, 2026, a modest decrease from \$264.3 million at October 31, 2025.
  • Current Assets: \$222.7 million, reflecting the company’s liquidity and ability to meet short-term obligations.
  • Inventory: \$119.7 million, which is relatively high compared to revenues and may indicate slower turnover or excess inventory.
  • Total Liabilities: The report shows various line items including accounts payable, accrued expenses, deferred credits, and other liabilities. Notably, the company maintains no preferred stock outstanding, and the equity base remains strong relative to liabilities.
  • Shareholders’ Equity: Remains robust, with no dilution from preferred shares as none are outstanding. The authorized preferred shares remain at 1,000,000 but none have been issued.

Other Comprehensive Income

  • Foreign Currency Translation Losses: The company reported translation losses, indicating some impact from international operations and currency fluctuations.
  • Derivative Instruments: The company recognized gains and reclassifications related to derivative instruments, with the net impact factored into comprehensive income.

Share Information

  • Outstanding Shares: As of February 28, 2026, Hurco had approximately 6,425,000 shares of common stock outstanding.
  • Trading Information: Shares are traded under the symbol HURC on The Nasdaq Stock Market LLC.
  • Reporting Status: Hurco is an accelerated filer and is not considered an emerging growth or shell company. All required reports and interactive data files have been submitted on time.

Potentially Price-Sensitive Developments

  • Significant Swing to Loss: The transition from a profit of \$4.3 million in Q1 2025 to a net loss of \$3.8 million in Q1 2026 is a substantial negative development. This could drive volatility in the share price, as it signals either a market downturn, operational challenges, or both.
  • Revenue Decline: A sharp year-over-year drop in revenues may raise red flags for investors about ongoing demand for Hurco’s products and/or competitive pressures.
  • Inventory Levels: Elevated inventory, especially in the face of shrinking sales, could indicate potential write-down risks or cash flow challenges if market conditions do not improve.
  • Comprehensive Losses: The impact of foreign currency and derivatives on comprehensive income adds further complexity and risk to the financial outlook.

Risks and Disclosures

  • The report includes standard risk factors and legal proceeding disclosures. However, there are no specific mentions of new litigation or extraordinary items in the section provided.
  • No evidence of a shell company status, and the company remains compliant with SEC reporting requirements.

Conclusion

Investors should note that Hurco Companies, Inc. experienced a challenging quarter, marked by a swing from profitability to a notable loss and a decline in revenues. These results are likely to be viewed negatively by the market and could put downward pressure on the share price in the near term. The company’s strong equity base and lack of preferred stock are positives, but the elevated inventory and comprehensive income losses highlight ongoing risks. Shareholders should closely monitor subsequent quarters for signs of operational recovery or further deterioration.


Disclaimer: This article is for informational purposes only and is not intended as investment advice. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. The information herein is based on the company’s published quarterly report and is subject to change without notice.




View HURCO COMPANIES INC Historical chart here



Evolus, Inc. 2025 Annual Report: Business Overview, Products, Competition, Risks, and Regulatory Insights

Evolus, Inc. 2025 Annual Report: Key Takeaways and Investor Insights Company Overview Evolus, Inc. (Nasdaq: EOLS), headquartered in Newport Beach, California, is a medical aesthetics company focused on delivering innovative products in the cash-pay...

Palvella Therapeutics Announces $188 Million Public Offering of 1,600,000 Shares – Underwriting Agreement Details and SEC Filing Information

Palvella Therapeutics, Inc. Announces \$200 Million Common Stock Offering Palvella Therapeutics, Inc. Announces \$200 Million Common Stock Offering Key Developments Palvella Therapeutics, Inc. has entered into an underwriting agreement to issue 1,600,000 shares of...

ABVC BioPharma Annual Report: Pipeline Overview, Clinical Trials, Patents, and Key Risks in Biopharmaceutical Development 21405670

ABVC BioPharma, Inc. 2025 Annual Report: Key Insights for Investors ABVC BioPharma, Inc. 2025 Annual Report: Comprehensive Analysis & Price-Sensitive Developments As a financial reporter, I’ve reviewed the ABVC BioPharma, Inc. Form 10-K for...

   Ad